130 related articles for article (PubMed ID: 6722395)
1. Hormonal effects of apomorphine in schizophrenia.
Ferrier IN; Johnstone EC; Crow TJ
Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
[TBL] [Abstract][Full Text] [Related]
2. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
[TBL] [Abstract][Full Text] [Related]
3. Anterior pituitary hormone secretion in chronic schizophrenia--an approach to neurohumoral mechanisms.
Johnstone EC; Crow TJ; Mashiter K
Psychol Med; 1977 May; 7(2):223-8. PubMed ID: 877185
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
[TBL] [Abstract][Full Text] [Related]
5. Noradrenergic and dopaminergic interrelation in schizophrenia.
Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
[TBL] [Abstract][Full Text] [Related]
6. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
7. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
Whalley LJ; Christie JE; Brown S; Arbuthnott GW
Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
9. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
[TBL] [Abstract][Full Text] [Related]
11. Clinical effects of apomorphine in schizophrenia.
Ferrier IN; Johnstone EC; Crow TJ
Br J Psychiatry; 1984 Apr; 144():341-8. PubMed ID: 6372924
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
Mueller GP; Simpkins J; Meites J; Moore KE
Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced growth hormone and prolactin responses in schizophrenia research.
Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
[TBL] [Abstract][Full Text] [Related]
15. Hormones, dopamine receptors and schizophrenia.
Meltzer HY; Busch D; Fang VS
Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
[No Abstract] [Full Text] [Related]
16. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
17. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J
Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291
[TBL] [Abstract][Full Text] [Related]
19. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
